Skip to main contentSkip to main content
You have permission to edit this article.
spotlight AP

Marketing of diabetes drugs for weight loss ignites debate

  • 0

The long list of side effects that follow ads for the newer expensive drugs to treat Type 2 diabetes sometimes include an unusual warning: They might cause weight loss. That side effect is one that many people — especially those with Type 2 diabetes, which is associated with obesity — may desperately want.

So it’s no surprise that some of the same drugs are being reformulated and renamed by manufacturers as a new obesity treatment. No longer limited to the crowded field of treatments for Type 2 diabetes, which affects about 10% of Americans, they join the far smaller number of drugs for obesity, which affects 42% of Americans and is ready to be mined for profit.

One that recently hit the market — winning Food and Drug Administration approval in June — is Novo Nordisk’s Wegovy, a higher-dose version of the company’s injectable diabetes drug Ozempic.

Ozempic’s peppy ads suggest that people who use it might lose weight, but also include a disclaimer: that it “is not a weight loss drug.” Now — with a new name — it is. And clinical trials showed using it leads to significant weight loss for many patients.

“People who go on this medication lose more weight than with any drug we’ve seen, ever,” said Dr. Fatima Cody Stanford, an obesity medicine specialist at Massachusetts General Hospital and Harvard Medical School who was not involved with any of the clinical trials.

But that leaves employers and insurers in the uncomfortable position of deciding if it’s worth it.


The arrival of a new class of weight loss drugs has created a thicket of issues for those who will pay for them.

Wegovy’s monthly wholesale price tag — set at $1,349 — is about 58% more than Ozempic’s, although, the company points out, the drug’s injector pens contain more than twice as much of the active ingredient. Studies so far show that patients may need to take it indefinitely to maintain weight loss, translating to a tab that could top $323,000 over 20 years at the current price. Weight loss treatments are not universally covered by insurance policies.

The arrival of this new class of weight loss drugs — one from Lilly may soon follow — has created a thicket of issues for those who will pay for them. The decision is complicated by many unknowables concerning their long-term use and whether competition might eventually lower the price.

“The metric we try to use is value,” said James Gelfand, senior vice president for health policy at the ERISA Industry Committee, or ERIC, which represents large, self-insured employers. “If we pay for this drug, how much is this going to cost and how much value will it provide to the beneficiaries?”

Weight loss treatments have had a lackluster past in this regard, with only modest results. Many employers and insurers likely remember Fen-Phen, a combination of fenfluramine and dexfenfluramine that was pulled from the market in the late 1990s for causing heart valve problems.

New drugs like Wegovy, more effective but also pricier than previous weight loss treatments, will add more fuel to that debate.

Past treatments were shown to prompt weight loss in the range of 5% to 10% of body weight. But many had relatively serious or unpleasant side effects.

Wegovy, however, helped patients lose an average of 15% of their body weight over 68 weeks in the main clinical trial that led to its approval. A comparison group that got a placebo injection lost an average of 2.5% over the same period. On the high end, nearly a third of patients in the treatment group lost 20% or more. Both groups had counseling on diet and exercise.

Side effects, generally considered mild, included nausea, diarrhea, vomiting and constipation. A few patients developed pancreatitis, a serious inflammation of the pancreas. Like the diabetes medication, the drug carries a warning about a potential risk of a type of thyroid cancer.

Weight loss in those taking Wegovy puts it close to the 20% to 25% losses seen with bariatric surgery, said Stanford at Mass General, and well above the 3% to 4% seen with diet and other lifestyle changes alone.

Participants also saw reductions in their waistlines and improvements in their blood pressure and blood sugar levels, which may mean they won’t develop diabetes, said Dr. Sean Wharton, an internal medicine specialist and adjunct professor at York University in Toronto who was among the co-authors of the report outlining the results of the first clinical trial on Wegovy.

Since weight loss is known to reduce the risk of heart attack, high blood pressure and diabetes, might the new drug type be worth it?

Covering such treatment would be a sea change for Medicare, which specifically bars coverage for obesity medications or drugs for “anorexia, weight loss or weight gain,” although it does pay for bariatric surgery. Pharmaceutical companies, patient advocates and some medical professionals are backing proposed federal legislation to allow coverage. But the legislation, the Treat and Reduce Obesity Act, has not made progress despite being reintroduced every year since 2012, and sponsors are now asking federal officials instead to rewrite existing rules.

Private insurers will have to consider a cost-benefit analysis of adding Wegovy to their list of covered treatments, either broadly or with limits. Obesity was first recognized as a disease by the American Medical Association, easing the path for insurance coverage, in 2013.

“Employers are going to have a bit of a challenge” deciding whether to add the benefit to insurance offerings, said Steve Pearson, founder and president of the Institute for Clinical and Economic Review, which provides cost-benefit analyses of medical treatments but has not yet looked at Wegovy.

The trade-offs are embodied in patients like Phylander Pannell, a 49-year-old Largo, Maryland, woman who said she lost 65 pounds in a clinical trial of Wegovy. That study gave the drug to all participants for the first 20 weeks, then randomly assigned patients to get either the drug or a placebo for the next 48 weeks to determine what happens when the medication is stopped. Only after the trial ended did she find out she was in the treatment group the entire time.

Her weight fell slowly at first, then ramped up, eventually bringing her 190-pound frame down to about 125. Pains in her joints eased; she felt better all around.

“I definitely feel the drug was it for me,” said Pannell, who also followed the trial’s guidance on diet and exercise.

The study found that both groups lost weight in the initial 20 weeks, but those who continued to get the drug lost an additional average of 7.9% of their body weight. Those who got a placebo gained back nearly 7%.

After the trial ended, and the COVID-19 pandemic hit, Pannell regained some weight and is now at 155. She is eager to get back on the medication and hopes her job-based insurance will cover it.

Scientists, employers, physicians and patients will have to decide whether the new drugs are worth it.

Earlier estimates — some commissioned by Novo Nordisk — of the potential cost of adding an obesity drug benefit to Medicare showed an overall reduction in spending when better health from the resulting weight loss was factored in.

Still, those earlier estimates considered much less expensive drugs, including a range of generic and branded drugs costing as little as $7 a month to more than $300, a small fraction of Wegovy’s cost.


(KHN (Kaiser Health News) is a national newsroom that produces in-depth journalism about health issues. Together with Policy Analysis and Polling, KHN is one of the three major operating programs at KFF (Kaiser Family Foundation). KFF is an endowed nonprofit organization providing information on health issues to the nation.)

©2021 Kaiser Health News. Distributed by Tribune Content Agency, LLC.

More health news you can use:

  • Updated
  • 0

Of the COVID-19 variants that have been named, the most talked about is delta. But there are many more, named according to the Greek alphabet.

  • Updated
  • 0

What does the science say about the pros and cons of fructose? Here's what to know.

  • Updated
  • 0

The use of supplements like turmeric among those undergoing cancer treatment is a concern. They are not standardized like prescription medications.

  • Updated
  • 0

Swimming in cold water is generally safe, but some people should be cautious.

  • Updated
  • 0

There’s no evidence to support supplements as a way to prevent prostate cancer. It's best to focus on getting nutrients through a healthy diet.

  • Updated
  • 0

About one in seven fainting episodes stems from heart‑related problems.

  • Updated
  • 0

Avoiding red and processed meats has been a standard public health message for many years. But experts continue to debate the issue.


Build your health & fitness knowledge

* I understand and agree that registration on or use of this site constitutes agreement to its user agreement and privacy policy.

Related to this story

Most Popular

The white gunman charged in a deadly, racist rampage inside a Buffalo supermarket didn’t need to travel abroad for tactical training, nor did he need to join an organization of like-minded militants who shared his world view. All Payton Gendron needed on his path to radicalization was exposure on the internet to a stew of hate-filled conspiracies, peddled in some cases by white killers whose massacres he had extensively researched online. The 18-year-old now stands accused in a murderous assault that left 10 Black people dead, and the rant-filled diatribe attributed to him fits an all-too-familiar profile — an aggrieved white man driven to violence by racist extremism.

COVID-19 emergency declarations for Nevada ended Friday. The public health agency for metro Las Vegas says it will continue to monitor spread of the virus and provide assistance with vaccinating and testing as the pandemic continues. Most of Nevada's pandemic measures, including business restrictions and mask mandates, have already been lifted, but the Southern Nevada Health District said it was important to remind the public that the virus that causes COVID-19 continues to circulate. Gov. Steve Sisolak on Thursday signed a proclamation ending the emergency Friday, a planned action he announced two weeks ago. His administration is now focused on the state's recovery.

Pennsylvania’s lieutenant governor and a top Democratic candidate for U.S. Senate, John Fetterman, is recovering from a stroke he says was caused by a heart condition called atrial fibrillation. In a statement Sunday, Fetterman says doctors quickly and completely removed the clot. A cardiologist and chair of the Department of Preventive Medicine at Northwestern University, Dr. Donald Lloyd-Jones, says people who develop A-fib are almost always put on a blood-thinning medication for the rest of their lives. He says that helps prevent the stroke-causing blood clots that untreated A-fib can create.

Twenty years after a spate of deaths at a rural Missouri hospital, a former worker has been charged with murder. According to a police investigator, in the five months that Jennifer Anne Hall was a respiratory therapist at Hedrick Medical Center, the Chillicothe hospital experienced 18 “code blue” incidents. The hospital historically averaged one such sudden cardiac event each year. Nine of the patients died, and nine recovered. Livingston County's prosecutor says Fern Franco died of lethal doses of a muscle relaxant and the pain reliever morphine. Hall’s attorney says she didn't have access to those or any other drugs. He said Hall became a scapegoat because of an arson conviction that she was cleared of in 2005.

Dr. Scott Jensen, a skeptic of the government’s response to COVID-19, has won the Minnesota GOP’s endorsement to challenge Democratic Gov. Tim Walz in the November election. After a wild ride, Jensen went over the top on the ninth ballot with 65% of the vote. Jensen led on the first two ballots, then regained the lead on the seventh ballot. Jensen’s comeback ended a surge by business executive Kendall Qualls, who fell to 33% on the final ballot after taking the lead on the fourth. Minnesota GOP Chairman David Hann says he does not expect Jensen to face a serious challenge in the Aug. 9 primary,

The government website for requesting free COVID-19 at-home tests from the U.S. government is accepting a third round of orders. The White House announced Tuesday that U.S. households can request an additional eight free at-home tests. President Joe Biden committed to making 1 billion at-home tests available to the public free of charge, but the White House says just 350 million tests have been shipped to date. A third round of orders is possible because hundreds of millions of tests are still available. The latest round will bring to 16 the total number of free tests available to each household since the program was launched earlier this year. 

President Joe Biden is off to South Korea and Japan on a six-day trip aimed at building rapport with the Asian nations’ leaders. Biden will try to send a message to China that Russia’s faltering invasion of Ukraine should give Beijing pause about its own saber-rattling in the Pacific. Biden departed Thursday and is set to meet newly elected South Korean President Yoon Suk Yeol and Japanese Prime Minister Fumio Kishida. Their talks will touch on trade, the global supply chain and North Korea’s nuclear program. Biden will also meet with leaders of the alliance known as the Quad, which includes Japan, Australia and India.

Get up-to-the-minute news sent straight to your device.


News Alerts

Breaking News